Amphastar Pharmaceuticals: Undervalued with AMP-110 License Agreement

Amphastar Pharmaceuticals (AMPH) has announced an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology for AMP-110, a synthetic human hormone analog targeting inflammatory and autoimmune conditions in the US and Canada. The company's 90-day share price return has been 19.55%, despite a 23.40% 1-year total shareholder return loss. Amphastar is trading at $27.76 and has a 70% intrinsic discount metric and a 23% 1-year total shareholder loss. The stock's valuation reflects concerns about pricing pressure and increased competition.